Home » Stocks » BOLT

Bolt Biotherapeutics, Inc. (BOLT)

Stock Price: $16.37 USD -0.28 (-1.68%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 594.85M
Revenue (ttm) 67,000
Net Income (ttm) n/a
Shares Out 21.50M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $16.37
Previous Close $16.65
Change ($) -0.28
Change (%) -1.68%
Day's Open 16.72
Day's Range 16.15 - 16.72
Day's Volume 55,084
52-Week Range 16.00 - 43.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REDWOOD CITY, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine th...

1 week ago - GlobeNewsWire

Media Release

Other stocks mentioned: GMAB
1 week ago - GlobeNewsWire

Bolt's first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human study Bolt's first-in...

2 months ago - GlobeNewsWire

REDWOOD CITY, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the tar...

2 months ago - GlobeNewsWire

– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a total of $358 million in recent fundraising –

2 months ago - GlobeNewsWire

Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.

Other stocks mentioned: MASS, MDWT, NEXI, OCDX
3 months ago - 24/7 Wall Street

REDWOOD CITY, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced today the closing of its initial public offering of...

4 months ago - GlobeNewsWire

REDWOOD CITY, Calif.-- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage immuno-oncology company, announced...

4 months ago - GlobeNewswire

Bolt Biotherapeutics, a Phase 1/2 biotech developing targeted therapies for solid tumors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

4 months ago - NASDAQ

Bolt Biotherapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About BOLT

We are a clinical-stage immuno-oncology company developing tumor-targeted therapies. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the strength of the innate and adaptive immune systems by activating and recruiting myeloid cells, thereby re-programming the tumor microenvironment to invoke an adaptive immune response. We believe that this process leads to the development of systemic immunological memory achi... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Randall C. Schatzman, Ph.D.
Employees
65
Stock Exchange
NASDAQ
Ticker Symbol
BOLT
Full Company Profile

Financial Performance

In 2020, BOLT's revenue was $231,000, an increase of 7.44% compared to the previous year's $215,000. Losses were -$60.73 million, 99.2% more than in 2019.

Financial Statements